BusiNETvs - 28/05/2009 - Jean-Michel Métry, Groupe AARDEX

BusiNETvs, Sierre, May 28th, 2009 Copyright AARDEX®

Innovation dans le suivi thérapeutique des patients

BusiNETvs

Dr. Jean-Michel MétryCEO, AARDEX Group (CH)

BusiNETvs, Sierre, May 28th, 2009 Copyright AARDEX®

MEMS I 1987

BusiNETvs, Sierre, May 28th, 2009 Copyright AARDEX®

Breaking the downward spiral

BusiNETvs, Sierre, May 28th, 2009 Copyright AARDEX®

MEMS system

Medication Event Monitoring System (MEMS®)

MEMS® 6

Events recording and storage

MEMS® Reader

Communication device

www.viewcompliance.com

Internet

BusiNETvs, Sierre, May 28th, 2009 Copyright AARDEX®

Aardex Group products & strengthsIN

FOR

MAT

ION

Number of openings during the day

Time since last dose taken

Nothing

Compliance index

Basic feedback to the patient

BusiNETvs, Sierre, May 28th, 2009 Copyright AARDEX®

MEMS 7

BusiNETvs, Sierre, May 28th, 2009 Copyright AARDEX®

SCL

Detection scheme

Signal detection

Noise Pill out

Manipulation

Prototype

Contact between 2 conductive layers

Mechanical action

BusiNETvs, Sierre, May 28th, 2009 Copyright AARDEX®

SCL: development status

BusiNETvs, Sierre, May 28th, 2009 Copyright AARDEX®

Research prototype 2009

BusiNETvs, Sierre, May 28th, 2009 Copyright AARDEX®

Technology platform

CORE IPAARDEX Group

New IP

BusiNETvs, Sierre, May 28th, 2009 Copyright AARDEX®

Days

Per

cent

0 100 200 300

0.4

0.5

0.6

0.7

0.8

0.9

1.0

Innovation and taxonomy

Non acceptancePerfect adherence

Treatment discontinuation

PKC: N ~ 20,000 patientsSource: AARDEX (Pharmionic database)

BusiNETvs, Sierre, May 28th, 2009 Copyright AARDEX®

Innovation and regulation: EU-ABC project

BusiNETvs, Sierre, May 28th, 2009 Copyright AARDEX®

Innovation and networking

PatientsFamiliesPatients associations

Health care providers

Pharma industry

Insurers

Heathcare systems & Drug regulators

Research community

PhysicianPharmacistNurse

End users

iAdherence

B. Vrijens, Feb 2008

BusiNETvs, Sierre, May 28th, 2009 Copyright AARDEX®

Innovation and communication

BusiNETvs, Sierre, May 28th, 2009 Copyright AARDEX®

Innovation and publication

BusiNETvs, Sierre, May 28th, 2009 Copyright AARDEX®

Innovation and positioning

AAGUnique position

BusiNETvs, Sierre, May 28th, 2009 Copyright AARDEX®

Identification of current and future competitorsMWV & Stora Enso (e-blister)B & OM (Bang & Olufsen Medicom Helping Hand device)GlowCap (new in the market with a simple concept)e-Pill pure gadget company

Competitor Positioning Map (considering relevant variables)

AAG

e-Pill

B & OM MWV

Strora Enso

GlowCap

Price

Information

Innovation: competitor analysis

Innovation axis

As low as possible CoGMaximum information

BusiNETvs, Sierre, May 28th, 2009 Copyright AARDEX®

Persistent Non Persistent

Persistent 106(62%)(94%)

7(21%)(6%)

Non Persistent

65(38%)(71%)

27(79%)(29%)

Predictedbased on

the algorithm

Validation:Cutoff criteria (based on the ROC Curve): 0.1Number of neighbours: 20 Actual Observation

171(100%)

34(100%)

113

(100%)

92

(100%)

Sensitivity: 79%Specificity: 62%Positive Predictive Value: 29%Negative Predictive Value: 94%

Poor executers: it’s good to intervene anywayGood executers: it’s difficult to predict their

non-persistence based on theirquality of executions

205

Innovation: modelling and simulation

BusiNETvs, Sierre, May 28th, 2009 Copyright AARDEX®

Business Models

• What & Why: product and value propositionEM and modeling and/or simulation for the CT and intervention for the broader market with medAmigo intervention

• Where: target groups/customers and possible market segmentsFrom the pharmaceutical companies to the patients including third party payers, patients’ organizations,…

• How: possible strategy for market entry and positioningLarge pharma launch for new products and/or re-launch of existing products with innovative interactive packaging concept.

• Who: position in the value network and necessary partnershipsMostly be the end user who is, in our case the patient

• How to deliver: internal value chains and market distribution channelVia our existing channels and potentially new partners

• How much: cost structures and revenue generation mechanismFor every dollar spent at least one back

–

Innovation and new business model

Innovation and market opportunities

BusiNETvs, Sierre, May 28th, 2009 Copyright AARDEX®

Innovation and market potential

Clinical trial market (measurement no intervention)

Target customers:Pharmaceutical companiesUsers:Health care professionals and patients

BusiNETvs, Sierre, May 28th, 2009 Copyright AARDEX®

Innovation and evolution (cycles)

3.2 Interventional market (medAmigo intervention)

Target customers:Pharmaceutical companies, insurers,…Users:Health care professionals to patients

Market potential In US$ is going tobe billions of US$

BusiNETvs, Sierre, May 28th, 2009 Copyright AARDEX®

THANK YOU!